C10705: Autism Spectrum Disorder: A Treatment Approach
Value Proposition:
While there is no known single cause for autism, Inventors have determined that a population of patients with ASD that is not associated with Smith-Lemli-Opitz Syndrome has plasma sterol levels that are outside the typical range. Preliminary studies by the Inventors suggest that optimizing plasma sterol levels has a beneficial effect on social interactions, verbal and non-verbal communication. This concept can be developed into a treatment method for a subpopulation of patients with ASD by optimizing plasma sterol levels. A clinical trial is in progress.
ADVANTAGES - Treatment method supplements a measurable deficit in serum sterol levels in a population of patients with Autism Spectrum Disorders that is not associated with Smith-Lemli-Opitz Syndrome and can increase social, verbal and non-verbal behaviors for improved quality of life in patients and their families. - Therapeutic dietary supplement could potentially be developed with a variety of textures and flavors in order to increase compliance in a patient population with heightened sensitivities to food and drink.
Technical Details:
Autism is a complex developmental disability caused by neurological issues. It affects 1 in every 150 American children, and almost 1 in 94 boys. Autism is a spectrum disorder that affects each individual differently and at varying degrees. Both children and adults with Autism Spectrum Disorder (ASD) show difficulties in social interactions, verbal and non-verbal communication, and play activities. There is an unmet medical need for ways to improve development in social interaction and communication skills.
Looking for Partners:
This technology could be commercialized as a method to treat the symptoms of Autism Spectrum Disorder. The technology could be developed into a therapeutic supplement for patients with Autism Spectrum Disorder.
